{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Jelly",
    "query": {
      "intervention": "Placebo Jelly"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 537,
    "total_pages": 54,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Jelly&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-08T12:56:40.960Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02616250",
      "title": "MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Brimonidine 0.33% gel (Br)",
          "type": "DRUG"
        },
        {
          "name": "CD07805/47 (Br) placebo gel",
          "type": "OTHER"
        },
        {
          "name": "Ivermectin 1% cream (IVM)",
          "type": "DRUG"
        },
        {
          "name": "CD5024 (IVM) placebo cream",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2015-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 7,
      "location_summary": "Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616250"
    },
    {
      "nct_id": "NCT01993225",
      "title": "A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Androxal 12.5 mg/25 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Capsules",
          "type": "DRUG"
        },
        {
          "name": "AndroGel 1.62%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2014-01",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Garden City",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01993225"
    },
    {
      "nct_id": "NCT04992546",
      "title": "Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PRN473 (SAR444727)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Principia Biopharma, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2021-08-13",
      "completion_date": "2022-12-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 9,
      "location_summary": "Long Beach, California • Los Angeles, California • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sweetwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04992546"
    },
    {
      "nct_id": "NCT01048502",
      "title": "Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Fenofibrate (Tricor) tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lovaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 100,
      "start_date": "2010-01",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2016-02-19",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01048502"
    },
    {
      "nct_id": "NCT03920644",
      "title": "Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prevention of Nausea Associated With Motion Sickness",
        "Treatment of Nausea Associated With Motion Sickness"
      ],
      "interventions": [
        {
          "name": "Scopolamine Transdermal Patch [Transderm Scop]",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Naval Aeromedical Research Unit, Dayton",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 320,
      "start_date": "2019-04",
      "completion_date": "2021-03",
      "has_results": false,
      "last_update_posted_date": "2019-04-19",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03920644"
    },
    {
      "nct_id": "NCT02462187",
      "title": "Topical NVN1000 for the Treatment of External Genital and Perianal Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Genital Warts",
        "Perianal Warts"
      ],
      "interventions": [
        {
          "name": "NVN1000 8% Gel",
          "type": "DRUG"
        },
        {
          "name": "NVN1000 16%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "NVN1000 24%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novan, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 108,
      "start_date": "2015-06-12",
      "completion_date": "2016-10-17",
      "has_results": true,
      "last_update_posted_date": "2023-04-06",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 15,
      "location_summary": "Fountain Valley, California • Lomita, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462187"
    },
    {
      "nct_id": "NCT00909181",
      "title": "Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urge Urinary Incontinence",
        "Urinary Frequency"
      ],
      "interventions": [
        {
          "name": "Oxybutynin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Antares Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 626,
      "start_date": "2009-03",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-07-02",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00909181"
    },
    {
      "nct_id": "NCT03887936",
      "title": "Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Testosterone gel 1.62%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "35 Years to 70 Years · Male only"
      },
      "enrollment_count": 92,
      "start_date": "2019-10-01",
      "completion_date": "2025-10-08",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887936"
    },
    {
      "nct_id": "NCT00487734",
      "title": "Effect of Testosterone Replacement on Insulin Resistance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Testosterone gel",
          "type": "RADIATION"
        },
        {
          "name": "Placebo for testosterone gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "McGuire Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "20 Years to 65 Years · Male only"
      },
      "enrollment_count": 19,
      "start_date": "2007-08",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2012-10-23",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00487734"
    },
    {
      "nct_id": "NCT02044081",
      "title": "Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dental Caries"
      ],
      "interventions": [
        {
          "name": "C16G2 Rinse",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "C16G2 Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Armata Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-02",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2019-08-01",
      "last_synced_at": "2026-09-08T12:56:40.960Z",
      "location_count": 2,
      "location_summary": "Kalispell, Montana • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Kalispell",
          "state": "Montana"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02044081"
    }
  ]
}